Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANEB-001 THC challenge study in healthy occasional cannabis users
NL-OMON54271Phase 2Active, not recruiting
- Sponsor
- Anebulo Pharmaceuticals
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of drinabant in Cannabinoid intoxication and drug intoxication (6 arms), sponsored by Anebulo Pharmaceuticals. Primary endpoints: VAS Feeling High, VAS Alertness and 2 more. Started Dec 2021; status: active, not recruiting.
02
Drugs
drinabant
03
Conditions
Cannabinoid intoxicationdrug intoxication
Beyond the preview
Go deeper on NL-OMON54271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54271.